EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4

Helena M A Feenstra iD, Issam El Mansori, Thomas J van Rijssen iD, Roula Tsonaka, Roselie M H Diederen iD, Carel B Hoyng, Reinier O Schlingemann, Camiel J F Boon iD, Elon H C van Dijk

Acta Ophthalmologica · 2026

DOI: 10.1111/aos.70106 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Acta Ophthalmologica, 2026. Verfasst von Helena M A Feenstra und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Central Serous Chorioretinopathy, Photochemotherapy, Eplerenone, Visual Acuity. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Stichting Blindenhulp, Algemene Nederlandse Vereniging ter voorkoming van Blindheid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Assessing the 24‐month treatment outcome of half‐dose photodynamic therapy (PDT) or oral eplerenone in chronic central serous chorioretinopathy (cCSC).

Methods

Multicentre randomized clinical trial included cCSC patients from the SPECTRA trial who were randomized to receive half‐dose PDT or oral eplerenone. Outcomes were evaluated at 24 months, including the primary outcome measure of complete resolution of subretinal fluid (SRF) on optical coherence tomography (OCT) and the secondary outcome measures best‐corrected visual acuity (BCVA), retinal and foveal sensitivity on microperimetry and the National Eye Institute Visual Functioning Questionnaire 25 (NEI‐VFQ25) score.

Results

At baseline, 107 patients were included, of which 80 patients attended the final visit at 24 months: 40 had been randomized to primary treatment with half‐dose PDT and 40 to eplerenone. In the eplerenone group, as many as 36/40 (90%) needed crossover treatment at 3 months with half‐dose PDT due to persistent SRF, compared to 8/40 (20%) in the half‐dose PDT group. At the final visit, complete SRF resolution was observed in 32/40 (80%) who were primarily treated with half‐dose PDT and in 35/40 (88%) who received primary eplerenone treatment ( p = 0.609). There were no significant differences in terms of BCVA, foveal sensitivity, retinal sensitivity and NEI‐VFQ25 score.

Conclusions

This study provides evidence for the long‐term efficacy of half‐dose PDT in resolving SRF and improving functional outcomes in cCSC. Even when patients initially received eplerenone treatment that did not result in complete SRF resolution, crossover treatment with half‐dose PDT led to similar (long‐term) group outcomes compared to half‐dose PDT as initial treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Serous ChorioretinopathyPhotochemotherapyEplerenoneVisual AcuityVerteporfinHumansMaleFollow-Up StudiesFemaleAdministration, OralMineralocorticoid Receptor AntagonistsTomography, Optical CoherenceFluorescein AngiographyChronic DiseasePhotosensitizing AgentsTreatment OutcomeMiddle AgedTime FactorsFundus OculiDose-Response Relationship, DrugAdult

Stichwörter der Autor:innen

central serous chorioretinopathyeplerenonehalf‐dose photodynamic therapyrandomized controlled trialsubretinal fluid

Substanzen

EplerenoneMineralocorticoid Receptor AntagonistsPhotosensitizing AgentsVerteporfin

Autor:innen und Institutionen

  • Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Ophthalmology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Ophthalmology, Fondation Asile des Aveugles, Jules-Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland.
  • Department of Vitreoretinal Surgery, Rotterdam Eye Hospital, Rotterdam, the Netherlands.

ORCID-Profile: Helena M A Feenstra, Thomas J van Rijssen, Roselie M H Diederen, Camiel J F Boon

Förderung

  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • Stichting Blindenhulp
  • Algemene Nederlandse Vereniging ter voorkoming van Blindheid
  • Stichting Blinden-Penning
  • Stichting Retina Fonds
  • Stichting MaculaFonds
  • Universiteit Leiden
  • Stichting voor Ooglijders

Zitieren

APA

Feenstra, H. M. A., El Mansori, I., van Rijssen, T. J., Tsonaka, R., Diederen, R. M. H., Hoyng, C. B., Schlingemann, R. O., Boon, C. J. F., & van Dijk, E. H. C. (2026). Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4. Acta Ophthalmologica. https://doi.org/10.1111/aos.70106

Vancouver

Feenstra HMA, El Mansori I, van Rijssen TJ, Tsonaka R, Diederen RMH, Hoyng CB, et al. Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4. Acta Ophthalmologica. 2026. doi:10.1111/aos.70106

BibTeX
@article{Feenstra2026,
  author = {Feenstra, Helena M A and El Mansori, Issam and van Rijssen, Thomas J and Tsonaka, Roula and Diederen, Roselie M H and Hoyng, Carel B and Schlingemann, Reinier O and Boon, Camiel J F and van Dijk, Elon H C},
  title = {Long‐term follow‐up of chronic central serous chorioretinopathy patients receiving oral eplerenone and half‐dose photodynamic therapy in the SPECTRA trial: SPECTRA trial report No. 4},
  journal = {Acta Ophthalmologica},
  year = {2026},
  doi = {10.1111/aos.70106}
}
Kostenlos starten →